TriStar Health Partners

  • Home
  • About
    • TriStar
    • Team
  • News
  • Investment Strategy
    • Investment Strategy
    • Economic Development Fund – TN Investco
  • Portfolio
  • Contact

NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment

December 10, 2015 By tstventures2015

NuSirt Biopharma today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its development program focused on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). NuSirt also announced the start of enrollment for its Phase 2A clinical trial targeting this disease at nine U.S. research sites. (Read More)

Filed Under: News

Our Portfolio


VIEW MORE

Subscribe to News & Events

Contact Us

Thank you for your interest in TriStar Health Partners. If you have questions or need further information, please contact us!

TriStar Health Partners

3322 West End Ave, Suite 1100 | Nashville, TN 37203
615.515-9880

Copyright © 2023 TriStar Technology Ventures. All rights reserved (CC-licensed photos excepted).